Th17 Cells as Potential Probiotic Therapeutic Targets in Inflammatory Bowel Diseases
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Inflammatory bowel diseases (IBD) are characterized by wasting and chronic intestinal inflammation triggered by various cytokine-mediated pathways. In recent years, it was shown that T helper 17 (Th17) cells are involved in the pathogenesis of IBD, which makes them an attractive therapeutic target. Th17 cells preferentially produce interleukin (IL)-17A–F as signature cytokines. The role of the interplay between host genetics and intestinal microbiota in the pathogenesis of IBD was demonstrated. Probiotics are live microorganisms that when orally ingested in adequate amounts, confer a health benefit to the host by modulating the enteric flora or by stimulating the local immune system. Several studies indicated the effectiveness of probiotics in preventing and treating IBD (ulcerative colitis, and Crohn’s disease). Furthermore, there is mounting evidence of probiotics selectively targeting the Th17 lineage in the prevention and management of inflammatory and autoimmune diseases such as IBD. This review highlights critical roles of Th17 cells in the pathogenesis of IBD and the rationale for using probiotics as a novel therapeutic approach for IBD through manipulation of Th17 cells. The potential molecular mechanisms by which probiotics modulate Th17 cells differentiation and production are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145
Transforming growth factor-β induces development of the TH17 lineage
Mangan, P. R., Harrington, L. E., O'Quinn, D. B., Helms, W. S., Bullard, D. C., Elson, C. O., Hatton, R. D., Wahl, S. M., Schoeb, T. R., & Weaver, C. T. (2006) · Nature · doi:10.1038/nature04754 · Cited by 3,087
A protective function for interleukin 17A in T cell–mediated intestinal inflammation
O'Connor Jr, W., Kamanaka, M., Booth, C. J., Town, T., Nakae, S., Iwakura, Y., Kolls, J. K., & Flavell, R. A. (2009) · Nature Immunology · doi:10.1038/ni.1736 · Cited by 756
Ford, A. C., Quigley, E. M. M., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Moayyedi, P. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.202 · Cited by 747 · cited 1×
“The efficacy of probiotics in IBD has been examined in various animal models and clinical studies, and respective outcomes were reviewed by several authors [1,3,31,41,51,53,54].”
BackgroundRegulation of inflammatory responses by IL-17F
Yang, X. O., Chang, S. H., Park, H., Nurieva, R., Shah, B., Acero, L., Wang, Y.-H., Schluns, K. S., Broaddus, R. R., Zhu, Z., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071978 · Cited by 739 · cited 1×
“It was also revealed that murine DSS-induced colitis was worsened in IL-17A-knockout mice but was substantially improved in IL-17F-knockout mice [25].”
BackgroundModulation of human dendritic cell phenotype and function by probiotic bacteria
Hart, A. L., Lammers, K., Brigidi, P., Vitali, B., Rizzello, F., Gionchetti, P., Campieri, M., Kamm, M. A., Knight, S. C., & Stagg, A. J. (2004) · Gut · doi:10.1136/gut.2003.037325 · Cited by 555
An update on the use and investigation of probiotics in health and disease
Sanders, M. E., Guarner, F., Guerrant, R., Holt, P. R., Quigley, E. M., Sartor, R. B., Sherman, P. M., & Mayer, E. A. (2013) · Gut · doi:10.1136/gutjnl-2012-302504 · Cited by 503 · cited 3×
“Consequently, upon consumption, probiotic bacteria or cell wall components are internalized by M cells to interact with dendritic cells, which further influence the polarization of T-cell responses (Th1, Th2, or regulatory T cells) [40].”
BackgroundGupta, P., Andrew, H., Kirschner, B. S., & Guandalini, S. (2000) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/00005176-200010000-00024 · Cited by 429
Griffin, G. K., Newton, G., Tarrio, M. L., Bu, D.-X., Maganto-Garcia, E., Azcutia, V., Alcaide, P., Grabie, N., Luscinskas, F. W., Croce, K. J., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200385 · Cited by 364 · cited 1×
“[27] found that IL-17 enhanced expression of neutrophilic chemokines CXCL1, CXCL2, and CXCL5 through endothelial activation.”
BackgroundRIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis
Takahashi, N., Vereecke, L., Bertrand, M. J. M., Duprez, L., Berger, S. B., Divert, T., Gonçalves, A., Sze, M., Gilbert, B., Kourula, S., et al. (2014) · Nature · doi:10.1038/nature13706 · Cited by 318 · cited 1×
“Using a specific Ripk1 mice model, it was established that mice developed severe intestinal inflammation due to IEC death and subsequent dysfunction of the intestinal barrier function [39].”
BackgroundTh17 cells: from precursors to players in inflammation and infection
Awasthi, A., & Kuchroo, V. K. (2009) · International Immunology · doi:10.1093/intimm/dxp021 · Cited by 241 · cited 1×
“Although controversial, it has been suggested that Th17 cells may confer a protective effect on the GI tract under steady-state homeostatic regulation, but initiate an uncontrolled pathogenic immune response during dysbiosis [5,15–18].”
BackgroundReview article: probiotics and prebiotics in irritable bowel syndrome
SPILLER, R. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03750.x · Cited by 190
Probiotic Effects on Inflammatory Bowel Disease1,
Sheil, B., Shanahan, F., & O’Mahony, L. (2007) · The Journal of Nutrition · doi:10.1093/jn/137.3.819s · Cited by 167 · cited 3×
“The efficacy of probiotics in IBD has been examined in various animal models and clinical studies, and respective outcomes were reviewed by several authors [1,3,31,41,51,53,54].”
Background
Cited by
Microbiota in health and diseases
Hou, K., Wu, Z.-X., Chen, X.-Y., Wang, J.-Q., Zhang, D., Xiao, C., Zhu, D., Koya, J. B., Wei, L., Li, J., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00974-4 · Cited by 3,171
Human gut microbiota in health and disease: Unveiling the relationship
Afzaal, M., Saeed, F., Shah, Y. A., Hussain, M., Rabail, R., Socol, C. T., Hassoun, A., Pateiro, M., Lorenzo, J. M., Rusu, A. V., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.999001 · Cited by 762
The Gut Microbiota in Inflammatory Bowel Disease
Qiu, P., Ishimoto, T., Fu, L., Zhang, J., Zhang, Z., & Liu, Y. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.733992 · Cited by 591
Intermittent Fasting Confers Protection in CNS Autoimmunity by Altering the Gut Microbiota
Cignarella, F., Cantoni, C., Ghezzi, L., Salter, A., Dorsett, Y., Chen, L., Phillips, D., Weinstock, G. M., Fontana, L., Cross, A. H., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.006 · Cited by 568
Lazar, V., Ditu, L.-M., Pircalabioru, G. G., Gheorghe, I., Curutiu, C., Holban, A. M., Picu, A., Petcu, L., & Chifiriuc, M. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01830 · Cited by 525
Metadata
- Authors
- Owaga, E., Hsieh, R.-H., Mugendi, B., Masuku, S., Shih, C.-K., & Chang, J.-S.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2015-09-01
- Volume
- 16
- Issue
- 9
- Pages
- 20841-20858
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2165966813
- Cited by
- 127
- References
- 13
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.